Today, we sit down with Dr. Lior Shaltiel of NurExone Biologics to explore how exosome-based delivery of siRNA could redefine CNS repair. We discuss why exosomes might overcome safety and manufacturing hurdles that hampered cell therapies, how early preclinical signals are guiding a rigorous first-in-human path, how endpoints and patient realities shape trial design, and the broader potential of exotherapy as a platform for regenerative medicine. This conversation highlights leadership in translating promising science into a practical regulatory and business strategy amid a challenging funding climate.